Literature DB >> 16271944

Catheter ablation therapy for atrial fibrillation.

Joseph E Marine1, Jun Dong, Hugh Calkins.   

Abstract

Since cases were first reported in 1994, catheter ablation of atrial fibrillation has undergone rapid development and expansion. The procedure began as an attempt to recreate the Maze III operation with a catheter technique. Understanding the contribution of the pulmonary veins to the initiation and maintenance of atrial fibrillation led to dramatic changes in procedural technique. The segmental ostial and the circumferential approaches have emerged as the 2 dominant methods. Efforts continue in academic centers to better understand the pathophysiology of the arrhythmia and to further refine the ablation procedure to improve patient outcomes.

Entities:  

Mesh:

Year:  2005        PMID: 16271944     DOI: 10.1016/j.pcad.2005.06.011

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  5 in total

Review 1.  Case report: Cerebral air embolization in the electrophysiology laboratory during transseptal catheterization: curative treatment of acute left hemiparesis with prompt hyperbaric oxygen therapy.

Authors:  Pirooz Mofrad; Wassim Choucair; Pamela Hulme; Hans Moore
Journal:  J Interv Card Electrophysiol       Date:  2006-10-11       Impact factor: 1.900

Review 2.  Evaluating the left atrium by magnetic resonance imaging.

Authors:  Thomas H Hauser; Dana C Peters; John V Wylie; Warren J Manning
Journal:  Europace       Date:  2008-11       Impact factor: 5.214

Review 3.  Catheter Abalation for AF : Past, Present and Future.

Authors:  David Spragg; Hugh Calkins
Journal:  J Atr Fibrillation       Date:  2008-12-01

Review 4.  Catheter ablation of atrial fibrillation.

Authors:  Richard Weachter; Sara Baig
Journal:  Mo Med       Date:  2010 Jan-Feb

Review 5.  The ambiguous pulmonary venoatrial junction: a new perspective.

Authors:  Gabrielle P Konin; Vineet R Jain; John D Fisher; Linda B Haramati
Journal:  Int J Cardiovasc Imaging       Date:  2007-10-02       Impact factor: 2.357

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.